

VACCINES ASSESSMENT TEAM

STANDARD OPERATION PROCEDURE

Doc No: IMD/SOP/03	Version No: 2	Revise before: 15 June 2027
Effective date: 15 June 2024	Replaces: 01.06	Page 1 of 9
Approved by:	TL-VAX, date: 10 Jun 2024	UH-PQT, date: 13 Jun 2024

Once printed or copied from the Master, this document is no longer controlled and only valid on the day of printing or copying

1. OBJECTIVE

- 1.1. This SOP provides the procedures which are followed by the <u>IMD-PQS Secretariat</u> (Secretariat), the <u>IMD-PQS Working Group</u> (WG) and by all *Technical Specialists* (TS) commissioned by the <u>Secretariat</u> to withdraw <u>performance specifications</u>.
- 1.2. It is essential that each <u>performance specification</u> is regularly reviewed. As soon as it becomes evident that the <u>product</u> type described in the specification is no longer required to help meet WHO policy objectives, the specification is formally withdrawn.

2. SCOPE

- 2.1. Applicable to all <u>performance specifications</u> prepared under the IMD-PQS initiative, with the exception of syringes.
- 2.2. All immunization <u>products</u> in the following categories require an IMD-PQS <u>product</u> <u>performance specification</u>, with the exception of syringes:

(Syringes are prequalified on the basis of ISO standards, as described in the World Health Organization document: "Pre-qualification of single-use injection devices under the IMD-PQS system: Guidelines for manufacturers)

- E001: Cold rooms, freezer rooms, and related equipment
- E002: Refrigerated vehicles
- E003: Refrigerators and freezers
- E004: Cold boxes and vaccine carriers
- E005: Coolant-packs
- E006: Temperature monitoring devices
- E007: Cold chain accessories
- E010: Waste management equipment

3. CROSS-REFERENCES

Relevant KPI(s):	Nil
Background:	https://extranet.who.int/pqweb/immunization-devices



VACCINES ASSESSMENT TEAM

STANDARD OPERATION PROCEDUR

WITHDRAWING AN IMD-PQS PRODUCT PERFORMANCE SPECIFICATION		
Doc No: IMD/SOP/03	Version No: 2	Revise before: 15 June 2027
Effective date: 15 June 2024	Replaces: 01.06	Page 2 of 9

Approved by: TL-VAX, date: 10 Jun 2024 UH-PQT, date: 13 Jun 2024

Once printed or copied from the Master, this document is no longer controlled and only valid on the day of printing or copying

Under this SOP:	IMD/TP/03a: Standard letter A - Notification of specification withdrawal
Other QMS documents:	 MD/SOP/01: Developing and publishing an IMD-PQS product performance specification IMD/SOP/02: Reviewing and revising an IMD-PQS product performance specification IMD/SOP/04: Developing and publishing an IMD-PQS product verification protocol. IMD/SOP/05: Reviewing and revising an IMD-PQS product verification protocol. IMD/SOP/06: Withdrawing an IMD-PQS product verification
	 protocol. IMD/SOP/11: Removing a pre-qualified product from the IMD-PQS database

4. **DEFINITIONS**

A 1		
Approved installer	A person or organization approved by the legal manufacturer or	
	reseller as a competent installer of the system components and who	
	has been appointed by the Employer to carry out the	
	installation of the System.	
Device	A medical device such as a syringe or temperature monitor.	
IMD-PQS Secretariat	The WHO IMD-PQS Secretariat is responsible for sharing up-to-	
	date information on prequalified immunization	
	devices and products, as well as product alerts. It ensures that	
	the standards that apply to equipment maintenance,	
	manufacturing and product testing are current. The Secretariat	
	also coordinates product feedback reports and learnings from	
	product field monitoring. The Secretariat holds ultimate	
	responsibility for the IMD-PQS process and takes all final IMD-	
	PQS decisions, including the decision to award prequalified	
	status to a product or device	
IMD-PQS Working	IMD-PQS Working Group is comprised of the WHO (IMD-PQS	
Group (WG)	and Expanded Programme on Immunization), the United	
	Nations Children's Fund (UNICEF) Supply and Programme	
	Divisions, the Gavi, the Vaccine Alliance Secretariat, specialist	



VACCINES ASSESSMENT TEAM

STANDARD OPERATION PROCEDURE

Doc No: IMD/SOP/03	Version No: 2	Revise before: 15 June 2027
Effective date: 15 June 2024	Replaces: 01.06	Page 3 of 9
Approved by:	TL-VAX, date: 10 Jun 2024	UH-PQT, date: 13 Jun 2024

Once printed or copied from the Master, this document is no longer controlled and only valid on the day of printing or copying

	and the control of th
	agencies, partner organizations and other key stakeholders. In
	an advisory capacity through the WG structure, these actors
	offer a wide range of programmatic and technical expertise
	that supports the development, introduction and advancement
	of technologies that will meet countries' EPI needs for high-
	quality cold chain equipment and devices
Manufacturer	In the context of this SOP, the word manufacturer includes both
	legal manufacturers and resellers.
Legal manufacturer	The natural or legal person with responsibility for the design,
	manufacture, packaging and labelling of a product or device before it
	is placed on the market under their own name, regardless of whether
	these operations are carried out by that person themself or on their
	behalf by a third party.
	A legal manufacturer may commonly contract another company to
	manufacture products or devices sold under the legal manufacturer's
	name. A manufacturer that is contracted in this
	way is typically known as an Original Equipment Manufacturer, or
	OEM.
Performance	An IMD-PQS product performance specification is a published
Specification	standard which sets out the detailed performance requirements for
	an immunization-related product. A performance specification
	defines the functional requirements of a product and describes the
	environment within which it must operate. It also describes any
	interface and inter-changeability requirements. Although it should
	set out clear verification criteria, it must not attempt to describe how
	the functional requirements are to be met. Rather, stimulating the
	device manufacturer to determine how the functional requirements
	may be best met creates room for innovation.
Product	In this document, where the word 'product' is used on its own, it
1 Todact	includes device.
Reseller	A commercial entity, licensed to act on behalf of a legal
Reserve	manufacturer, and which carries product liability and warranty
	manaracturer, and winer carries product hability and warranty



VACCINES ASSESSMENT TEAM

WITHDRAWING AN IMD-PQS PRODUCT PERFORMANCE SPECIFICATION		
Doc No: IMD/SOP/03	Version No: 2	Revise before: 15 June 2027
Effective date: 15 June 2024	Replaces: 01.06	Page 4 of 9
Approved by:	TL-VAX, date: 10 Jun 2024	UH-PQT, date: 13 Jun 2024
Once printed or copied from the Master, this document is no longer controlled and only valid on the day of printing or copying		

	responsibilities no less onerous than those carried by the legal
	manufacturer
Universal design	The design of products and services that address the needs of the
	widest possible audience, irrespective of age or ability. Also called
	Inclusive Design or Design for all.
Verification protocol	Describes in detail how the performance of a product or device
	is tested or otherwise evaluated as part of the IMD-PQS
	product prequalification procedure. See IMD/SOP/4:
	Developing and publishing an IMD-PQS product verification
	protocol.

5. RESPONSIBILITIES

A Technical Specialist (TS)	Reviews the need for withdrawal and makes recommendations to the Secretariat.		
IMD-PQS Working Group (WG)	 Documents outdated performance specifications that should be withdrawn and informs the Secretariat; Sends the proposal to the IMD-PQS Secretariat (this may take place at any time); and Where requested by the Secretariat, solicits information and input from country EPI to that may inform prioritization of specification withdrawal. 		
IMD-PQS Secretariat	 Examines the proposal and, if satisfied of the need, directs that the withdrawal of the performance specification be commissioned; Commissions a Technical Specialist to review the specification that is commissioned for withdrawal; Requests WG review(s) of the specification commissioned for withdrawal; Arranges for peer review of the specification commissioned for withdrawal, and may also arrange for manufacturer review (at the discretion of the Secretariat); Takes the ultimate decision to approve the withdrawal of the specification; and 		



VACCINES ASSESSMENT TEAM

STANDARD OPERATION PROCEDURE


WITHDRAWING AN	IMD-PQS PRODUCT PERFORMA	NCE SPECIFICATION
IMD/COD/O3	Varsian No. 2	Boyica bafara, 15 lu

Approved by:	TL-VAX, date: 10 Jun 2024	UH-PQT, date: 13 Jun 2024
Effective date: 15 June 2024	Replaces: 01.06	Page 5 of 9
Doc No: IMD/SOP/03	Version No: 2	Revise before: 15 June 2027

Once printed or copied from the Master, this document is no longer controlled and only valid on the day of printing or copying

 Publishes the withdrawal of the specification to the IMD-PQS website and circulates it to the relevant members of staff of WHO, UNICEF and manufacturers.

6. HIGH LEVEL FLOW CHART SUMMARY





VACCINES ASSESSMENT TEAM

STANDARD	OPERATION	PROCEDURE
----------	------------------	------------------

WITHDRAWING AN IMD-PQS PRODUCT PERFORMANCE SPECIFICATION				
Doc No: IMD/SOP/03 Version No: 2 Revise before: 15 June 2027				
Effective date: 15 June 2024 Replaces: 01.06 Page 6 of 9				
Approved by:	TL-VAX, date: 10 Jun 2024	UH-PQT, date: 13 Jun 2024		
Once printed or copied from the Master, this document is no longer controlled and only valid on the day of printing or copying				

7. PROCESS STEPS

7.1. Identify the need for withdrawal (WG)

- 7.1.1. The <u>WG</u> advises the Secretariat of any <u>performance specification</u> which may need to be withdrawn for any of the following reasons:
 - Feedback from country EPI programmes;
 - WHO and UNICEF immunization programme changes;
 - Comments received from testing laboratories, technical specialists and <u>manufacturers</u> identifying fundamental technical shortcomings in the <u>specification</u>;
 - Feedback reports from field monitoring activities highlighting fundamental specification-related problems; or
 - Technical or other developments which may render a <u>performance specification</u> obsolete.

The <u>WG</u> sends its withdrawal proposals to the <u>Secretariat</u> for decision and approval. This can happen at any time but usually occurs at the next <u>IMD-PQS WG</u> quarterly meeting.

7.2. Approval for withdrawal (Secretariat)

7.2.1. The <u>Secretariat</u> takes the final decision on withdrawal of a <u>performance</u> specification.

7.3. Publication (Secretariat)

- 7.3.1. As soon as the withdrawal has been approved, the <u>Secretariat</u> notifies the affected <u>manufacturers</u> of the intended action.
- 7.3.2. Withdrawal notification and the associated timelines for <u>manufacturer</u> conformity must be reasonable and may vary on a case-by-case basis depending on the reason for withdrawal.
- 7.3.3. Standard letter A (IMD/TP/3a) can be used for this purpose.
- 7.3.4. Subsequently the <u>performance specification</u> is removed from the IMD-PQS website and replaced with a document describing the reason for the withdrawal.
- 7.3.5. Generally speaking, this action does not take place until at least six months after the affected manufacturers have been notified.
- 7.3.6. At the same time, notification of withdrawal is posted on the IMD-PQS database/catalogue website and the TechNet-21 website.



VACCINES ASSESSMENT TEAM

STANDARD OPERATION PROCEDURE

STANDARD OF ERATION I ROCEDORE				
WITHDRAWING AN IMD-PQS PRODUCT PERFORMANCE SPECIFICATION				
Doc No: IMD/SOP/03 Version No: 2 Revise before: 15 June 2027				
Effective date: 15 June 2024	Replaces: 01.06	Page 7 of 9		
Approved by:	TL-VAX, date: 10 Jun 2024	UH-PQT, date: 13 Jun 2024		
Once printed or copied from the Master, this document is no longer controlled and only valid on the day of printing or copying				

- 7.3.7. The <u>Secretariat</u> informs by email all <u>manufacturers</u> of IMD-PQS prequalified products affected by the <u>performance specification</u> withdrawal.
- 7.3.8. The Secretariat deletes all <u>products</u> covered by the <u>performance specification</u> from the database.
- 7.3.9. Refer to IMD/SOP/11 *Removing a prequalified product from the IMD-PQS database* for details of this procedure.

7.4. <u>Distribution</u> (Secretariat)

This SOP is to be distributed to the following individuals and groups:

- IMD-PQS Secretariat,
- IMD-PQS WG,
- WHO Expanded Programme on Immunization (EPI),
- UNICEF Supply Division and UNICEF Programme Division,
- Each Technical Specialist commissioned to work on any aspect of a specification,
- All relevant manufacturers,
- IMD-PQS and TechNet-21 websites.

8. RECORDS

- 8.1. The Secretariat saves product specifications in WHO ePQS-Box / Sharepoint: Folder "Specs, VPs & PQS Guides".
- 8.2. The Secretariat saves verification protocols in WHO ePQS-Box / Sharepoint: Folder "Specs, VPs & PQS Guides".
- 8.3. IMD Product Catalogue WHO IMD Prequalification Website: "WHO Catalogue of Prequalified Immunization Devices".

9. REVISION HISTORY

Version	Reason for revision	Author	Drafted
01.06	1. ATT team was changed to QSS team due	Drafted by O.	06/01/2007
	to the reorganization in the IVB	Afsar Approved	
	Department.	by U. Kartoğlu	
	2. The code VML was changed to IMD-PQS		
	in the SOP No.s for easy reference.		
	3. The person responsible for giving no-		
	objection clearance for the		



VACCINES ASSESSMENT TEAM

STANDARD OPERATION PROCEDURE

Approved by:	TL-VAX, date: 10 Jun 2024	UH-PQT, date: 13 Jun 2024
Effective date: 15 June 2024	Replaces: 01.06	Page 8 of 9
Doc No: IMD/SOP/03	Version No: 2	Revise before: 15 June 2027

Once printed or copied from the Master, this document is no longer controlled and only valid on the day of printing or copying

		specifications		
	4.	was identified as the QSS Coordinator.		
01.06	1.	Hyperlink to each IMD-PQS category	Drafted by P.	27/01/2017
		added in the 'Purpose' clause.	Mallins	
	2.	Footnotes defining the IMD-PQS Working	Approved by I.	
		Group and the IMD-PQS Secretariat	Gobina	
		added in Clause 5 Responsibilities		
	3.	IMD-PQS system structure simplified,		
		removing FMWG, Steering Group.		
		IVB/QSS is also renamed EMP/PQT.		
		Revisions to this SOP reflect these		
		changes (text and figures).		
	4.	'Responsibilities' clause revised to)
		separate out specific responsibilities of		
		key actors and to remove process		
	_	elements.		
	5.	Clause 7.4 'Distribution' edited to		
		include complete group of		
	6	stakeholders.		
	6.	'Terms & definitions' moved to annex, revised, definitions updated in line		
		with WG reviews of IMD-PQS glossary		
		Feb 2018.		
	7	Sub-clauses of 7'Annual technical		
	/.	review' and 'Extraordinary technical		
		review' removed as standalone sections.		
	8.	Concrete example of a reason for		
		specification withdrawal added to IMD-TP-		
		3a		
02	1		Approved by I.	01/2024
	1. 2.	Updating to new RPQ format New department, unit and team names	Gobina	
	3.	Changed supervisors name from Group		
	ا.	Lead to Team Lead		
	4.	Assignment of IMD as code for the		
		product stream on PQ of immunization		
	1	1		



VACCINES ASSESSMENT TEAM

STANDARD OPERATION PROCEDURE

Doc No: IMD/SOP/03	Version No: 2	Revise before: 15 June 2027	
Effective date: 15 June 2024	Replaces: 01.06	Page 9 of 9	
Approved by:	TL-VAX, date: 10 Jun 2024	UH-PQT, date: 13 Jun 2024	
Once printed or copied from the Master, this document is no longer controlled and only valid on the day of printing or copying			

devices and equipment and used for numbering of QMS documents	
numbering of Qivis documents	
5. Inclusion of KPIs and their targets where	
applicable	
6. Transforming some annexes into	
templates related to the SOP	
7. PQS updated to IMD-PQS (Immunization	
Devices Performance, Quality and Safety	()